

高エネルギー医学研究部門

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
寺崎 一典	高エネルギー 医学研究部門	准教授	博士(医学)	核薬学 放射線薬品学 分子イメージング	<p>①Kimura K, Kubo Y, Dobashi K, Katakura Y, Chida K, Kobayashi M, Yoshida K, Fujiwara S, Terasaki K, Kawamura T, Ogasawara K. Angiographic, Cerebral hemodynamic, and cognitive outcomes of indirect revascularization surgery alone for adult patients with misery perfusion due to ischemic moyamoya disease. Neurosurgery. 90(6):676-683(2022)</p> <p>②Igarashi S, Ando T, Takahashi T, Yoshida J, Kobayashi M, Yoshida K, Terasaki K, Fujiwara S, Kubo Y, Ogasawara K. Development of cerebral microbleeds in patients with cerebral hyperperfusion following carotid endarterectomy and its relation to postoperative cognitive decline. J Neurosurg. 1:1-7(2021)</p> <p>③Iwata R, Terasaki K, Ishikawa Y, Harada R, Furumoto S, Yanai K, Pascali C. A concentration-based microscale method for 18F-nucleophilic substitutions and its testing on the one-pot radiosynthesis of [18F]FET and [18F]fallypride. Appl Radiat Isot. 166:109361(2020)</p> <p>④Takahashi T, Kobayashi M, Fujiwara S, Kubo Y, Terasaki K, Ogasawara K. Decrease in 18F-Florbetapir accumulation in the cerebral hemisphere with hypoperfusion and misery perfusion due to chronic atherosclerotic occlusion of the internal carotid artery. Clin Nucl Med. 45(2):e115-e116(2020)</p> <p>⑤Oikawa K, Kobayashi M, Beppu T, Terasaki K, Ogasawara K. Resolution of hypoxic tissue in cerebellar hemispheres after arterial bypass surgery in a patient with symptomatic bilateral vertebral artery occlusion: a 18F-FRP170 PET study. Clin Nucl Med. 44(4):295-296(2019)</p> <p>⑥Roppongi M, Izumisawa M, Terasaki K, Muraki Y, Shozushima M. 18F-FDG and 11C-choline uptake in proliferating tumor cells is dependent on the cell cycle in vitro. Ann Nucl Med. 33(4):237-243(2019)</p>
佐々木 敏秋	高エネルギー 医学研究部門	講師	博士(工学)	放射線科学 核医学	<p>①Beppu T, Iwaya T, Sato S, Nomura J, Terasaki K, Sasaki T, Yamada N, Fujiwara S, Sugai T, Ogasawara K. : PET with 11C-methyl-L-methionine as a predictor of consequential outcomes at the time of discontinuing temozolomide-adjuvant chemotherapy in patients with residual IDH-mutant lower-grade glioma/Clin Nucl Med. 47(7):569-574(2022)</p> <p>②Beppu T, Sato Y, Yamada N, Terasaki K, Sasaki T, Sugai T, Ogasawara K. : Impacts on histological features and 11C-methyl-L-methionine uptake after one-shot administration with bevacizumab before surgery in newly diagnosed glioblastoma/Transl Oncol. 12(11): 1480-1487(2019)</p> <p>③Beppu T, Sasaki T, Sato Y, Terasaki T. : High-uptake areas on 18F-FRP170 PET image necessarily include proliferating areas in glioblastoma : a superimposed image study combining 18F-FRP170 PET with 11C-methionine PET/Advances in Molecular Imaging. 7:1-11(2017)</p> <p>④Beppu T, Terasaki K, Sasaki T, Sato Y, Tomabechi M, Kato K, Sasaki M, Ogasawara K. : MRI and 11C-methyl-L-methionine PET differentiate bevacizumab true responders after initiating therapy for recurrent glioblastoma/Clin Nucl Med. 41(11):852-857 (2016)</p> <p>⑤Beppu T, Sasaki T, Terasaki K, Saura H, Mitsuura H, Ogasawara K, Sasaki M, Iwata R, Takai Y. : High-uptake areas on positron emission tomography with the hypoxic radiotracer 18F-FRP170 in glioblastomas include regions retaining proliferative activity under hypoxia/Ann Nucl Med. 29:336-341(2015)</p>